ERBB2 and cancer: A study by Haque et al., which included 13, 939 women, reported a pCR rate of 38.7% for HER2-positive cancers, with lower rates for triple- negative tumors (23.2%), Luminal B tumors (8.3%), and Luminal A tumors (0.3%) (21), which also reflects the trends observed in our study.